Ono Begins Trials for New Hepatocellular Carcinoma Therapy
This article was originally published in PharmAsia News
Ono Pharmaceuticals announced their July 2 submission of Phase 1 trial documentation for the hepatocellular carcinoma treatment peptid vaccine ONO-7268MX1, developed by Oncotherapy Science.
You may also be interested in...
Inovio forges ahead into Phase I trials with DNA-based vaccine candidate, but can it prove skeptics wrong?
With hospitals throughout the EU short of urgently needed COVID-19 medical supplies, including respiratory equipment, there are ways for companies to sell and deliver their products quickly.
Entries for the Scrip Awards are now open. Now in their 16th year, the Awards seek to reward the outstanding achievements of the pharmaceutical, biotech and allied industries in improving human health and will take place in London on 2 December.